Intended for healthcare professionals

Latest dermatology news


BMS teams up with Temedica develop an app for psoriasis patients

Bristol Myers Squibb (BMS) will collaborate with Temedica, a digital health and health insights company, to develop an app for patients living with psoriasis. The app will be available to all psoriasis patients in Germany.

23 Jun 2022

Galderma launches Rosacea Space to raise awareness

As part of Rosacea Awareness Month, Galderma revealed its new virtual platform, Rosacea Space, to show how the chronic condition ‘goes beyond the visible’

23 Jun 2022

Almirall reports positive results from phase 3 atopic dermatitis trials

Almirall has announced that its phase 3 studies in atopic dermatitis show that lebrikizumab results in clearer skin for the majority of patients. The drug was used for patients with moderate-to-severe atopic dermatitis as part of Almirall’s Advocate programme

23 Jun 2022

Sanofi shares positive trial results for prurigo nodularis

Positive results from the phase 3 PRIME2 trial – part of the LIBERTY-PN PRIME clinical programme – assessing the safety and effectiveness of Sanofi and Regeron’s Dupixent (dupilumab) were shared at the American Academy of Dermatology (AAD) 2022 Annual Meeting

23 Jun 2022

Janssen shares new clinical trial data for psoriasis treatment Tremfya

The Janssen Pharmaceutical Companies of Johnson & Johnson have announced results from phase 3 clinical trials that show that Tremfya (guselkumab) demonstrated consistent and durable skin clearance. The results, from the phase 3 VOYAGE 1 and VOYAGE 2 clinical trials, were evident in the majority of adult patients with moderate to severe plaque psoriasis over a five-year period

23 Jun 2022

Dupixent hits all endpoints in prurigo nodularis trial

Sanofi and Regeneron’s monoclonal antibody (mAb) Dupixent (dupilumab) met all primary and key secondary endpoints in a phase 3 trial for the chronic infammatory skin disease prurigo nodularis.

13 Jan 2022

The New England Journal of Medicine publishes pivotal studies of Tapinarof in plaque psoriasis

The New England Journal of Medicine has published results from its PSOARING 1 and PSOARING 2 pivotal trials for its investigational drug tapinarof topical cream, a novel, steroid-free, therapeutic aryl hydrocarbon receptor (AhR) modulating agent under development for the treatment of plaque psoriasis in adults.

13 Jan 2022

Global survey reveals impact of atopic dermatitis on children

A global survey, presented at the European Academy of Dermatology and Venereology (EADV) congress, has revealed the impact of atopic dermatitis (AD) on children and teenagers.

01 Nov 2021

Pilot study shows potential of new portable device for at-home BCC treatment

Findings from a pilot study show that a new prototype portable device that can be used to treat basal cell carcinoma at home signifcantly reduce pain levels while achieving efcacy comparable with a hospital stay.

28 Oct 2021

National review fnds link between long-term topical steroid use and skin withdrawal symptoms

A national review has found that individuals using topical steroids for long periods of time can sufer severe skin withdrawal side efects.

27 Oct 2021